BRIEF-Arrowhead Pharmaceuticals Presents New Data At Aha24

Reuters
18 Nov 2024

Nov 18 (Reuters) - Arrowhead Pharmaceuticals Inc

:

* ARROWHEAD PHARMACEUTICALS PRESENTS NEW DATA AT AHA24 FROM PALISADE PHASE 3 STUDY AND OPEN-LABEL EXTENSION FROM MUIR AND SHASTA-2 STUDIES OF PLOZASIRAN

* ARROWHEAD PHARMACEUTICALS: MEAN REDUCTIONS IN TRIGLYCERIDES OF UP TO -73% IN PATIENTS FROM MUIR AND -86% IN PATIENTS FROM SHASTA-2 IN STUDY

* ARROWHEAD PHARMACEUTICALS: PLOZASIRAN INDUCED DEEP AND SUSTAINED REDUCTIONS IN TRIGLYCERIDES

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10